AMCP joined with other national pharmacy stakeholders to urge HHS to authorize pharmacists to order and administer COVID-19 vaccines when they become available.
AMCP joined with other health care stakeholders to urge Congressional leadership to bolster Medicaid funding due to the COVID-19 public health emergency.
CMS outlining proposed changes to the calculation of best price under the Medicaid Drug Rebate Program (MDRP), particularly how manufacturers should account for value-based purchasing programs.
On June 1, 2020, the FDA issued a RFI requesting stakeholder comments on updating and improving the Orange Book. Please send any feedback to advocacy@amcp.org by August 14, 2020.
On June 1, 2020, the FDA issued a RFI soliciting stakeholder input on the listing of patent information in the Orange Book, including on the types of patent currently listed and how changes to current patent listing practices may impact drug product development. Please send any feedback to advocacy@amcp.org by August 14, 2020.
AMCP joined with national pharmacy stakeholder organizations in issuing a statement of commitment to advocate against racial injustice and all forms of discrimination and to work to eliminate the resulting inequities in patient care.